Listing of Claims:

This listing of claims reflects all claim amendments and replaces all prior versions, and listings, of claims in the application. Material to be inserted is in **bold and underline**, and material to be deleted is in ~~strikeout~~ or (if the deletion is of five or fewer consecutive characters or would be difficult to see) in double brackets [[ ]].

Please cancel claims 4, 5, and 6.

Please amend claims 1, 2, 3, and 7 as indicated below.

Please add new claims 8-13.

1. (Currently Amended) **A method of treating a mammal in which migration of monocytes or T lymphocytes is increased, or production of IL-10 is increased, and inhibition of said increase is desired, comprising: administration** ~~The use~~ of a compound represented ~~with~~ **by** the following general formula (I) for inhibiting MCP-1 production:



... (I)

[~~wherein,~~ **wherein** R^1 represents a hydrogen atom or a group of the following formula (II) or (III):



... (II)



... (III)

[~~wherein,~~ **wherein** the groups of formula (II) and formula (III) may also be their pharmaceutically acceptable **salts** ~~salts~~];

R^2 represents COOH or a group of the following formula (IV):



... (IV)

or their pharmaceutically acceptable salts;

X represents C=O or CH; and,

dotted lines suitably represent a double **bond;** ~~bond~~]

provided that said compound represented by the formula (I) is not MUN-014.

2. (Currently Amended) The ~~use~~ **method** according to claim 1 wherein, the pharmaceutically acceptable salts in the above formulas (II), (III) and (IV) are sodium salts, potassium salts, ammonium salts or combinations thereof.

3. Currently Amended) The ~~use~~ **method** ~~of a compound~~ according to claim **8** ~~1~~ wherein, a compound of the above general formula (I) is one of either:

olean-11,13(18)-diene-30-carboxy-3β-yl-(disodium 2-O-β-glucopyranuronosyl-β-D-glucopyranuronate);

sodium olean-3β-hydroxy-11-oxo-12-ene-30-ate;

disodium olean-9(11),12-diene-3β,30-diol-3β,30-O-dihemiphthalate;

~~disodium olean-11,13(18)-diene-3β,30-diol-3β,30-O-dihemiphthalate;~~

disodium olean-3β-hydroxy-11,13(18)-diene-30-ate-3β-O-hemiphthalate;

disodium olean-3β-hydroxy-11-oxo-12-ene-30-ate-3β-O-hemiphthalate; or

monoammonium 20β-carboxy-11-oxo-30-norolean-12-en-3β-yl-2-O-β-D-glucopyranuronosyl-β-D-

glucopyranosidouronate.

4 (Canceled)

5. (Canceled)

6. (Canceled)

7. (Currently Amended) A pharmaceutical composition for treatment or prevention of decreases in infection resistance to opportunistic infections occurring in burn patients, AIDS patients, cancer patients, encephalitis patients, individuals ~~having~~ **who have** suffered serious injuries or undergone major surgery, individuals subject to stress or other individuals in which production of MCP-1 has been induced, comprising:

a compound according to ~~claim 1~~ **any one of claims 1 2, 3 and 8**, along with an arbitrary pharmaceutically acceptable carrier, in an amount effective for treating or preventing decreases in infection resistance to opportunistic infections occurring in said individuals.

8. (New) The method according to claim 2, wherein the pharmaceutically acceptable salts are sodium salts or ammonium salts.

9. (New) A method of treating or preventing decreases in infection resistance, comprising: administration of a compound represented by the following general formula (I) for inhibiting MCP-1 production:



... (I)

wherein R^1 represents a hydrogen atom or a group of the following formula (II) or (III):



... (II)



... (III)

wherein, the groups of formula (II) and formula (III) may also be their pharmaceutically acceptable salts;

R^2 represents COOH or a group of the following formula (IV):



... (IV)

or their pharmaceutically acceptable salts;

X represents C=O or CH; and

dotted lines suitably represent a double bond,

provided that said compound represented by the formula (I) is not MUN-014.

10. (New) The method according to claim 9, wherein the pharmaceutically acceptable salts in the above formulas (II), (III) and (IV) are sodium salts , potassium salts, ammonium salts or combinations thereof.

11. (New) The method according to claim 10, wherein the pharmaceutically acceptable salts are sodium salts or ammonium salts.

12. (New) The method according to claim 11, wherein a compound of the above general formula (I) is one of either:

olean-11,13(18)-diene-30-carboxy-3β-yl-(disodium 2-O-β-

glucopyranuronosyl-β-D-glucopyranuronate);

sodium olean-3β-hydroxy-11-oxo-12-ene-30-ate;

disodium olean-9(11) , 12-diene-3β, 30-diol-3β , 30-O-dihemiphthalate;

disodium olean-3β-hydroxy-11, 13 (18) -diene-30-ate-3 β-O-hemiphthalate;

disodium olean-3β-hydroxy-ll-oxo-12-ene-30-ate-3β-0-hemiphthalate; or

monoammonium 20β-carboxy-11-oxo-30-norolean-12-en-3β-yl-2-O-β-D-glucopyranuronosyl-β-D-glucopyranosidouronate.

13. (New) The method according to any one of claims 9 to 12, wherein the decreases in infection resistance are decreases in infection resistance to opportunistic infections occurring in burn patients, AIDS patients, cancer patients, encephalitis patients, individuals who have suffered serious injuries or undergone major surgery, or individuals subject to stress or other individuals in which production of MCP-1 has been induced.